Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP.

Published byClaud Miller Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP."— Presentation transcript:

1 Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP cells. U-251/TCTP cells and H-4/TCTP cells were transfected with control shRNA (Ctrl shRNA) or TCF-4 shRNA1. TCTP levels were detected through immunostaining with the TCTP antibody, and actin was used as a loading control. (B) In vitro growth of U-251/TCTP cells treated with nonsense control shRNA (Ctrl shRNA), or TCF-4 shRNA1 was measured using MTT assays. (C) In vitro growth of H-4/TCTP cells treated with nonsense control shRNA (Ctrl shRNA), or TCF-4 shRNA1 was measured using MTT assays. (D) In vitro growth of U-251/V cells treated with nonsense control shRNA (Ctrl shRNA) or TCF-4 shRNA1 was measured using MTT assays. (E) In vitro growth of H-4/V cells treated with nonsense control shRNA (Ctrl shRNA), or TCF-4 shRNA1 was measured using MTT assays. (F) Average tumor volume (left) and tumor TCF-4/Ki67 staining (5 weeks after implantation, right) in athymic nude mice subcutaneously inoculated with U-251/TCTP treated with nonsense control shRNA (Ctrl shRNA) or TCF-4 shRNA1. (G) Average tumor volume (left) and tumor TCF-4/Ki67 staining (5 weeks after implantation, right) in athymic nude mice subcutaneously inoculated with H-4/TCTP treated with nonsense control shRNA (Ctrl shRNA) or TCF-4 shRNA1. (H) Another TCF-4 shRNA called TCF-4 shRNA2 was used to knock down TCF-4. U-251/TCTP, and H-4/TCTP cells were transfected with control shRNA (Ctrl shRNA) or TCF-4 shRNA2. TCTP levels were detected through immunostaining with TCTP antibody, and actin was used as a loading control. (I) In vitro growth of U-251/TCTP cells treated with nonsense control shRNA (Ctrl shRNA), or TCF-4 shRNA2 was measured using MTT assays. (J) In vitro growth of H-4/TCTP cells treated with nonsense control shRNA (Ctrl shRNA), or TCF-4 shRNA2 was measured using MTT assays. (K) In vitro growth of U-251/V cells treated with nonsense control shRNA (Ctrl shRNA) or TCF-4 shRNA2 was measured using MTT assays. (L) In vitro growth of H-4/V cells treated with nonsense control shRNA (Ctrl shRNA), or TCF-4 shRNA2 was measured using MTT assays. (M) Average tumor volume (left) and tumor TCF-4/Ki67 staining (5 weeks after implantation, right) in athymic nude mice subcutaneously inoculated with U-251/TCTP treated with nonsense control shRNA (Ctrl shRNA) or TCF-4 shRNA2. (N) Average tumor volume (left) and tumor TCF-4/Ki67 staining (5 weeks after implantation, right) in athymic nude mice subcutaneously inoculated with H-4/TCTP treated with nonsense control shRNA (Ctrl shRNA) or TCF-4 shRNA2. For A–E and H­L), the results represent at least 3 separate experiments. For F, G, M, and N, n = 10 mice/group. Error bar: ±S.D. From: TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription Neuro Oncol. 2013;16(2): doi: /neuonc/not194 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please 1

Download ppt "Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP."

Similar presentations

Arginase I enhances vascular smooth muscle cell proliferation by increasing intracellular polyamine production (A and B) Arginase I enhances cell proliferation.

Arginase I enhances vascular smooth muscle cell proliferation by increasing intracellular polyamine production (A and B) Arginase I enhances cell proliferation.
From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 6 Gene expression and DNA methylation in callus

Fig. 6 Gene expression and DNA methylation in callus
Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model  Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model  Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,
Introduction Conclusions

Introduction Conclusions
Figure 4. Naturally occurring senescent cells from a HER2-expressing patient-derived xenograft secrete IL-6, which is required for tumor growth. A ) A.

Figure 4. Naturally occurring senescent cells from a HER2-expressing patient-derived xenograft secrete IL-6, which is required for tumor growth. A ) A.
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 
From: Political Leadership and Power Redistribution

From: Political Leadership and Power Redistribution
The role of galectin-1 in in vitro and in vivo photodynamic therapy with a galactodendritic porphyrin  Patrícia M.R. Pereira, Sandrina Silva, José S.

The role of galectin-1 in in vitro and in vivo photodynamic therapy with a galactodendritic porphyrin  Patrícia M.R. Pereira, Sandrina Silva, José S.
Cell Physiol Biochem 2013;32: DOI: /

Cell Physiol Biochem 2013;32: DOI: /
Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,

Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,
Fig. 1 Increased MIR155HG expression correlates with glioma grade and mesenchymal transition and confers a poor prognosis in GBM patients. (A) The level.

Fig. 1 Increased MIR155HG expression correlates with glioma grade and mesenchymal transition and confers a poor prognosis in GBM patients. (A) The level.
Fig. 1. Neem induces caspase-3 activation and cell death in multiple cancer cell types. ( A ) HCT116 cells were treated with neem for 0, 12, 24 and 36h,

Fig. 1. Neem induces caspase-3 activation and cell death in multiple cancer cell types. ( A ) HCT116 cells were treated with neem for 0, 12, 24 and 36h,
Cell Physiol Biochem 2016;38: DOI: /

Cell Physiol Biochem 2016;38: DOI: /
Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM

Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.

Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
Fig. 1 Proportion of study participants with ideal Cardiovascular Health Metrics by self-rated health. Ideal category of Cardiovascular Health Metrics.

Fig. 1 Proportion of study participants with ideal Cardiovascular Health Metrics by self-rated health. Ideal category of Cardiovascular Health Metrics.

Similar presentations

Ads by Google